Physician profile
Michael T Pham
NPI 1477940658
$3,840.73
in general payments reported to CMS, 2019-2025
21 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.54 · 2021: $138 · 2022: $876 · 2023: $1,283 · 2024: $487 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,164.38 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $719.75 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $465.00 | 2021-2025 | |
| Pfizer INC. | $372.05 | 2023-2025 | |
| Lilly USA, LLC | $190.14 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Biohaven Pharmaceutical Holding Company LTD. | $164.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $154.19 | 2023 | Xarelto |
| Lundbeck LLC | $87.15 | 2025 | Vyepti |
| Idorsia Pharmaceuticals US INC | $84.31 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $60.31 | 2022-2023 | Eliquis |
| Ibsa Pharma INC. | $60.05 | 2021-2023 | Tirosint, Licart |
| Viiv Healthcare Company | $50.80 | 2024 | Apretude |
| Amgen INC. | $49.02 | 2022-2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.43 | 2023 | Tradjenta |
| Amarin Pharma, INC. | $40.03 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $30.00 | 2025 | Invega Sustenna |
| Alcon Vision LLC | $24.54 | 2020 | |
| Glaxosmithkline, LLC. | $24.53 | 2024 | Bexsero |
| Incyte Corporation | $24.36 | 2025 | Opzelura |
| Abbott Laboratories | $16.45 | 2025 | Freestyle Libre 3 |
| Phadia US INC. | $13.28 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.